Skip to content
OpenCapital
Get started

Nuvation Bio NUVB Revenue Interest Financing Liability Noncurrent

Revenue Interest Financing Liability Noncurrent at other companies

LQD
Liquidia CorporationLQDA
$127.64M+23.7%
LQD
Liquidia CorporationLQDA
$50.22M+33.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$343.91M+3.7%
uniQure logo
uniQureQURE
$482.33M+8.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$40.32M+17.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$655K+331%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:RevenueInterestFinancingLiabilityNoncurrent.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's revenue interest financing liability noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's revenue interest financing liability noncurrent?
Nuvation Bio (NUVB) reported revenue interest financing liability noncurrent of $4.24M in Q4 2025.
What does revenue interest financing liability noncurrent mean?
This represents the long-term portion of obligations under revenue interest financing agreements that are due beyond the next fiscal year. It quantifies the long-term commitment of future product royalties or revenue streams to capital providers. This metric is essential for evaluating the long-term debt burden and the impact of financing choices on future profitability.